2 days ago
1
Amgen (NASDAQ:AMGN) stock dipped on Wednesday following an update from its partner, Zai Lab (NASDAQ:ZLAB), regarding the late-stage trial of bemarituzumab combined with chemotherapy.
The interim analysis of the trial, which focused on first-line gastric cancer treatment, revealed a significant improvement in
English (US) ·